# A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

> **NCT00787891** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 127 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** rabeprazole
- **DRUG:** rabeprazole

## Key facts

- **NCT ID:** NCT00787891
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2013-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787891, "A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00787891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*